Metropolis Healthcare DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.76×	0.74×	0.76×
	0.96×	0.97×	0.98×	0.93×	0.94×
	16.8%	16.2%	14.6%	15.6%	17.3%
	0.82×	0.82×	0.78×	0.79×	0.76×
	1.40×	1.40×	1.40×	1.41×	1.52×
	13.6%	13.4%	11.9%	11.9%	14.4%
	13.4%	13.4%	12.0%	12.3%	15.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

METROPOLIS₹553.85

Metropolis Healthcare Ltd.

· Pharma & Health

₹ CrorePeersLALPATHLAB VIJAYA THYROCARE MARKSANS PARKHOSPS JLHL RUBICON HCGMcap ₹11,483 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.76	0.74	0.76	0.74	0.74
Interest Burden (Pretax/EBIT) ×	0.94	0.93	0.98	0.97	0.96
EBIT Margin %	17.34	15.58	14.60	16.23	16.78
Asset Turnover ×	0.76	0.79	0.78	0.82	0.82
Financial Leverage (Assets/Equity) ×	1.52	1.41	1.40	1.40	1.40
ROE (5-step product, year-end total equity) %	14.39	11.89	11.93	13.36	13.64
ROE (owners' profit / average owners' equity) %	15.25	12.26	11.95	13.36	13.36

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.